| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| SpringWorks Therapeutics, Inc. | Chief Commercial Officer | Common Stock | 56.3K | $2.68M | $47.62 | Apr 1, 2024 | Direct |
| SpringWorks Therapeutics, Inc. | Chief Commercial Officer | Stock Option (Right to Buy) | 75K | Jan 4, 2024 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
|---|---|---|---|---|---|---|---|
| SWTX | SpringWorks Therapeutics, Inc. | Apr 1, 2024 | 1 | -$86.9K | 4 | Apr 3, 2024 | Chief Commercial Officer |
| SWTX | SpringWorks Therapeutics, Inc. | Feb 2, 2024 | 5 | -$381K | 4 | Feb 5, 2024 | Chief Commercial Officer |
| SWTX | SpringWorks Therapeutics, Inc. | Jan 4, 2024 | 4 | -$155K | 4 | Jan 8, 2024 | Chief Commercial Officer |
| SWTX | SpringWorks Therapeutics, Inc. | Apr 3, 2023 | 1 | -$34.7K | 4 | Apr 5, 2023 | Chief Commercial Officer |
| SWTX | SpringWorks Therapeutics, Inc. | Jan 5, 2023 | 3 | -$45.8K | 4 | Jan 9, 2023 | Chief Commercial Officer |
| SWTX | SpringWorks Therapeutics, Inc. | Apr 1, 2022 | 2 | -$83.3K | 4 | Oct 13, 2022 | Chief Commercial Officer |
| SWTX | SpringWorks Therapeutics, Inc. | Jan 6, 2022 | 2 | $0 | 4 | Jan 10, 2022 | Chief Commercial Officer |